Analystreport

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.

Oramed Pharmaceuticals Inc.  (ORMP) 
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm Check Earnings Report
US:NASDAQ Investor Relations: oramed.com/investors